文献速递艾滋病与性传播感染

多替拉韦/拉米夫定与多替拉韦联合替诺福韦艾拉酚胺/恩曲他滨对初治HIV-1感染者病毒储存库及炎症影响的随机临床试验

Randomized clinical trial to evaluate the longitudinal HIV-1 reservoir and inflammation in treatment-naïve people starting dolutegravir/lamivudine versus dolutegravir plus tenofovir alafenamide/emtricitabine.
PubMed 文献 · Clin Microbiol Infect · 2025-10-03

这项IV期开放标签多中心随机试验将初治HIV-1感染者分配至多替拉韦/拉米夫定(DTG/3TC)组或多替拉韦+替诺福韦艾拉酚胺/恩曲他滨(DTG+TAF/F)组,比较24个月内CD4+ T细胞相关HIV-1-DNA和HIV-1-RNA变化。结果显示两组在完整及缺陷病毒DNA下降、免疫恢复、T细胞活化/增殖/耗竭标志物及血浆炎症因子降低方面均无显著差异,提示起始DTG+TAF/F相较DTG/3TC并未带来额外获益。

要点

  • 初治HIV-1感染者启动DTG/3TC与DTG+TAF/F在24个月病毒储存库下降上无显著差异。
  • 两组免疫恢复及T细胞活化、增殖、耗竭标志物变化相似。
  • 两组血浆IL-1β、IL-6、TNF-α、IFN-γ、sCD14、sCD163下降幅度无显著差异。

核心结论

  • 起始DTG+TAF/F方案相较DTG/3TC方案并未在病毒储存库、免疫激活或炎症指标上带来额外获益。

研究设计与样本

  • IV期、对照、开放标签、多中心随机临床试验,初治HIV-1感染者随机接受DTG+TAF/F或DTG/3TC。
  • 共66例参与者随机化,其中DTG/3TC组30例、DTG+TAF/F组29例完成随访。

主要发现

  • 第24个月时,DTG+TAF/F组与DTG/3TC组完整HIV-1-DNA分别从基线的1210(412-3508)和1230(335-2502) copies/10^6 CD4+降至65(24-236)和71(32-110)(F=0.253;p=0.691)。
  • 总缺陷HIV-1-DNA分别从基线的831(315-1636)和726(273-1770) copies/10^6 CD4+降至143(82-368)和266(67-353)(F=1.840,p=0.201)。
  • 两组在免疫恢复、T细胞活化/增殖/耗竭标志物下降及血浆IL-1β、IL-6、TNF-α、IFN-γ、sCD14、sCD163水平降低上均无显著差异。

关键数值与推荐

  • 完整HIV-1-DNA检测采用Intact Proviral DNA Assay,HIV-1-RNA检测采用Intact Viral RNA Assay。

临床怎么用

  • 对于初治HIV-1感染者,选择DTG/3TC两药方案或DTG+TAF/F三药方案在24个月内的病毒储存库及炎症控制效果相当,可依据其他因素个体化选择。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There is limited evidence on whether dolutegravir/lamivudine (DTG/3TC) reduces the viral reservoir, immune activation, and inflammation as a three-drug regimen. This study aims to clarify possible differences in these outcomes in people with HIV-1 (PHIV) starting DTG plus tenofovir alafenamide/emtricitabine (DTG + TAF/F) versus DTG/3TC. METHODS: A phase IV, controlled, open-label, multicentre clinical trial in which treatment-naïve PHIV were randomized to DTG + TAF/F or DTG/3TC. The primary endpoint was changes in CD4+ T cells associated with HIV-1-DNA and HIV-1-RNA after 12 and 24 months (Intact Proviral DNA and Intact Viral RNA Assays). Secondary endpoints included immune recovery and changes in T-cell phenotypes and plasma inflammatory markers. STATISTICS: χ2, Mann-Whitney U test, and general linear model for repeated measures. RESULTS: Sixty-six participants were randomized, of whom 30 (DTG/3TC) and 29 (DTG + TAF/F) completed follow-up. Overall, the median baseline CD4+/μL count was 401 (293-540), the CD4+/CD8+ ratio 0.47 (0.34-0.76), and the viral load 57 250 copies/mL (16 189-180 500). Results are reported as medians (interquartile ranges) in the DTG + TAF/F and DTG/3TC groups at baseline and month 24, respectively. Intact HIV-1-DNA: 1210 (412-3508) copies/106 CD4+ and 1230 (335-2502), which decreased to 65 (24-236) and 71 (32-110) (F = 0.253; p = 0.691). Total defective HIV-1-DNA: 831 copies/106 CD4+ (315-1636) and 726 (273-1770), decreasing to 143 copies/106 CD4+ (82-368) and 266 (67-353) (F = 1.840, p = 0.201). Similarly, no significant differences were observed between the groups in immune recovery, decrease in activation, proliferation, and exhaustion markers of T cells, as well as in the reduction of plasma levels of interleukin-1β, interleukin-6, tumour necrosis factor-α, interferon-γ, sCD14, and sCD163. CONCLUSIONS: These data suggest that starting treatment with DTG + TAF/F does not confer benefits over DTG/3TC.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Saborido-Alconchel A, Serna-Gallego A, Trujillo-Rodriguez M, et al. Randomized clinical trial to evaluate the longitudinal HIV-1 reservoir and inflammation in treatment-naïve people starting dolutegravir/lamivudine versus dolutegravir plus tenofovir alafenamide/emtricitabine. Clin Microbiol Infect. 2025. PMID: 41047097. doi:10.1016/j.cmi.2025.09.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。